Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
NCT02055690 · The Christie NHS Foundation Trust · PHASE1/PHASE2 · terminated · last registry update 2021-05-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Safety” | – | Registry record, The Christie NHS Foundation Trust |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-04-29Also stopped (terminated): Dana-Farber Cancer Institute, PTK787/ZK 222584 + paclitaxel (NCT00358163)
- 2022-04-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Cabozantinib (NCT03141177)
- 2022-04-19Results posted on the registry: National Cancer Institute (NCI), Sunitinib (NCT03641326)
- 2022-04-19Also stopped (terminated): National Cancer Institute (NCI), Sunitinib (NCT03641326)
- 2022-04-05Results posted on the registry: City of Hope Medical Center, pazopanib hydrochloride (NCT01157091)
- 2022-03-31Also stopped (terminated): Academic and Community Cancer Research United, Ascorbic Acid + Pazopanib Hydrochloride (NCT03334409)
- 2022-03-22Results posted on the registry: Heidelberg University, Pazopanib + Paclitaxel (NCT02212015)
- 2022-03-22Also stopped (terminated): Heidelberg University, Pazopanib + Paclitaxel (NCT02212015)
- 2022-03-18Results posted on the registry: Federation Francophone de Cancerologie Digestive, sunitinib malate + Placebo (NCT01164202)
- 2022-03-16Results posted on the registry: Academic and Community Cancer Research United, Ascorbic Acid + Pazopanib Hydrochloride (NCT03334409)
- 2022-03-09Results posted on the registry: Five Prime Therapeutics, Inc., Cabiralizumab + Nivolumab (NCT02526017)
- 2022-02-15Also stopped (withdrawn): Guru Sonpavde, Avelumab + Sunitinib (NCT03035630)
- 2022-01-26Phase 3 first posted: Cogent Biosciences, Inc., CGT9486 + CGT9486 (NCT05208047)
- 2022-01-11Results posted on the registry: Graybug Vision, Drug: GB-102 + Aflibercept (NCT03953079)
- 2021-12-02Results posted on the registry: OHSU Knight Cancer Institute, Edicotinib (NCT03557970)
- 2021-12-02Also stopped (terminated): OHSU Knight Cancer Institute, Edicotinib (NCT03557970)
- 2021-11-04Also stopped (terminated): OHSU Knight Cancer Institute, Dasatinib + Idelalisib (NCT01620216)
- 2021-10-29Also stopped (withdrawn): BioGene Pharmaceutical Ltd., Linifanib + BIBW2992 (NCT03481842)
- 2021-10-28Also stopped (terminated): SCRI Development Innovations, LLC, Pazopanib + Doxil (NCT01035658)
- 2021-10-19Results posted on the registry: NYU Langone Health, Nivolumab + Cabiralizumab (NCT03599362)
- 2021-10-19Also stopped (terminated): NYU Langone Health, Nivolumab + Cabiralizumab (NCT03599362)
- 2021-10-06Also stopped (terminated): Michael Weichenthal, PTK787/ZK 222584 + Dacarbazine (NCT00615160)
- 2021-10-04Results posted on the registry: OHSU Knight Cancer Institute, Dasatinib + Idelalisib (NCT01620216)
- 2021-09-24Results posted on the registry: Eisai Inc., Lenvatinib + Everolimus (NCT02811861)
- 2021-09-22Also stopped (terminated): GWT-TUD GmbH, pazopanib or guideline conform chemotherapy (NCT03735758)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision